Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Preferred Stock Liabilities (2021)

Nuvectis Pharma has reported Preferred Stock Liabilities over the past 1 years, most recently at $15.2 million for Q4 2021.

  • Quarterly results put Preferred Stock Liabilities at $15.2 million for Q4 2021, changed N/A from a year ago — trailing twelve months through Dec 2021 was $15.2 million (changed N/A YoY), and the annual figure for FY2021 was $15.2 million, changed.
  • Preferred Stock Liabilities reached $15.2 million in Q4 2021 per NVCT's latest filing, roughly flat from $15.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $15.2 million in Q3 2021 and bottomed at $11.2 million in Q2 2021.